Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1982 1
1983 4
1984 7
1985 7
1986 6
1987 7
1988 13
1989 28
1990 31
1991 23
1992 29
1993 25
1994 26
1995 26
1996 23
1997 26
1998 23
1999 27
2000 30
2001 28
2002 30
2003 46
2004 44
2005 31
2006 66
2007 66
2008 82
2009 80
2010 88
2011 98
2012 121
2013 138
2014 136
2015 134
2016 106
2017 133
2018 117
2019 96
2020 100
2021 84
2022 64
2023 64
2024 50
2025 38
2026 35

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,117 results

Results by year

Filters applied: . Clear all
Page 1
Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial.
Budoff MJ, Bhatt DL, Kinninger A, Lakshmanan S, Muhlestein JB, Le VT, May HT, Shaikh K, Shekar C, Roy SK, Tayek J, Nelson JR. Budoff MJ, et al. Eur Heart J. 2020 Oct 21;41(40):3925-3932. doi: 10.1093/eurheartj/ehaa652. Eur Heart J. 2020. PMID: 32860032 Free PMC article. Clinical Trial.
AIMS: Despite the effects of statins in reducing cardiovascular events and slowing progression of coronary atherosclerosis, significant cardiovascular (CV) risk remains. Icosapent ethyl (IPE), a highly purified eicosapentaenoic acid ethyl ester, added to a st …
AIMS: Despite the effects of statins in reducing cardiovascular events and slowing progression of coronary atherosclerosis, significant card …
Bioavailability of marine n-3 fatty acid formulations.
Dyerberg J, Madsen P, Møller JM, Aardestrup I, Schmidt EB. Dyerberg J, et al. Prostaglandins Leukot Essent Fatty Acids. 2010 Sep;83(3):137-41. doi: 10.1016/j.plefa.2010.06.007. Prostaglandins Leukot Essent Fatty Acids. 2010. PMID: 20638827 Clinical Trial.
Seventy-two volunteers were given approximately 3.3g of eicosapentaenoic acid (EPA) plus docosahexaenoic acid (DHA) daily for 2 weeks. Increases in absolute amounts of EPA and DHA in fasting serum triglycerides, cholesterol esters and phospholipids were exami …
Seventy-two volunteers were given approximately 3.3g of eicosapentaenoic acid (EPA) plus docosahexaenoic acid (DHA) dai …
Randomized Trial for Evaluation in Secondary Prevention Efficacy of Combination Therapy-Statin and Eicosapentaenoic Acid (RESPECT-EPA).
Miyauchi K, Iwata H, Nishizaki Y, Inoue T, Hirayama A, Kimura K, Ozaki Y, Murohara T, Ueshima K, Kuwabara Y, Tanaka-Mizuno S, Yanagisawa N, Sato T, Daida H; RESPECT-EPA Investigators. Miyauchi K, et al. Circulation. 2024 Aug 6;150(6):425-434. doi: 10.1161/CIRCULATIONAHA.123.065520. Epub 2024 Jun 14. Circulation. 2024. PMID: 38873793 Clinical Trial.
BACKGROUND: Low plasma levels of eicosapentaenoic acid (EPA) are associated with cardiovascular events. This trial aimed to assess the clinical benefits of icosapent ethyl in patients with coronary artery disease, a low EPA/arachidonic acid (AA) ratio, …
BACKGROUND: Low plasma levels of eicosapentaenoic acid (EPA) are associated with cardiovascular events. This trial aimed to as …
Effect of dietary supplementation with omega-3 fatty acid and gamma-linolenic acid on acne vulgaris: a randomised, double-blind, controlled trial.
Jung JY, Kwon HH, Hong JS, Yoon JY, Park MS, Jang MY, Suh DH. Jung JY, et al. Acta Derm Venereol. 2014 Sep;94(5):521-5. doi: 10.2340/00015555-1802. Acta Derm Venereol. 2014. PMID: 24553997 Clinical Trial.
This study was undertaken to evaluate the clinical efficacy, safety, and histological changes induced by dietary omega-3 fatty acid and gamma-linoleic acid in acne vulgaris. A 10-week, randomised, controlled parallel dietary intervention study was performed in 45 pa …
This study was undertaken to evaluate the clinical efficacy, safety, and histological changes induced by dietary omega-3 fatty acid a …
Effects of icosapent ethyl according to baseline residual risk in patients with atherosclerotic cardiovascular disease: results from REDUCE-IT.
Burger PM, Bhatt DL, Dorresteijn JAN, Koudstaal S, Mosterd A, Martens FMAC, Steg PG, Visseren FLJ; REDUCE-IT Investigators. Burger PM, et al. Eur Heart J Cardiovasc Pharmacother. 2024 Oct 4;10(6):488-499. doi: 10.1093/ehjcvp/pvae030. Eur Heart J Cardiovasc Pharmacother. 2024. PMID: 38678009 Free PMC article. Clinical Trial.
AIMS: Icosapent ethyl lowers triglycerides and significantly reduces major adverse cardiovascular events (MACE), though treatment effects may vary between individuals. ...Modification of the relative treatment effects of icosapent ethyl by baseline risk was assessed …
AIMS: Icosapent ethyl lowers triglycerides and significantly reduces major adverse cardiovascular events (MACE), though treatment eff …
Lipoprotein(a) Blood Levels and Cardiovascular Risk Reduction With Icosapent Ethyl.
Szarek M, Bhatt DL, Miller M, Brinton EA, Jacobson TA, Tardif JC, Ballantyne CM, Mason RP, Ketchum SB, Lira Pineda A, Doyle RT Jr, Steg PG; REDUCE-IT Investigators. Szarek M, et al. J Am Coll Cardiol. 2024 Apr 23;83(16):1529-1539. doi: 10.1016/j.jacc.2024.02.016. Epub 2024 Mar 25. J Am Coll Cardiol. 2024. PMID: 38530686 Free article. Clinical Trial.
OBJECTIVES: The aim of this post hoc analysis of REDUCE-IT (Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial) was to explore the cardiovascular benefit of icosapent ethyl (IPE) across a range of Lp(a) levels. ...
OBJECTIVES: The aim of this post hoc analysis of REDUCE-IT (Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Tria …
Effects of Long-Chain Polyunsaturated Fatty Acids in Combination with Lutein and Zeaxanthin on Episodic Memory in Healthy Older Adults.
Sueyasu T, Yasumoto K, Tokuda H, Kaneda Y, Obata H, Rogi T, Izumo T, Kondo S, Saito J, Tsukiura T, Nakai M. Sueyasu T, et al. Nutrients. 2023 Jun 21;15(13):2825. doi: 10.3390/nu15132825. Nutrients. 2023. PMID: 37447152 Free PMC article. Clinical Trial.
Arachidonic acid (ARA), docosahexaenoic acid (DHA), and eicosapentaenoic acid (EPA), which are long-chain polyunsaturated fatty acids (LCPUFAs), as well as lutein (L) and zeaxanthin (Z), can potentially improve brain function. ...
Arachidonic acid (ARA), docosahexaenoic acid (DHA), and eicosapentaenoic acid (EPA), which are long-chain polyun …
Eicosapentaenoic acid decreases inflammation and improves glucose homeostasis in patients with burns: a randomized clinical trial.
Mousavi MA, Mousavi SN, Shaghaghi A, Sabet SA. Mousavi MA, et al. Sci Rep. 2025 Nov 18;15(1):40551. doi: 10.1038/s41598-025-24292-1. Sci Rep. 2025. PMID: 41254027 Free PMC article. Clinical Trial.
The present study was designed to investigate the effects of fish oil containing 500 mg eicosapentanoic acid (EPA) on inflammatory markers and glucose homeostasis in patients with non-severe burns. ...
The present study was designed to investigate the effects of fish oil containing 500 mg eicosapentanoic acid (EPA) on inflammatory ma …
Comparative Bioavailability of DHA and EPA from Microalgal and Fish Oil in Adults.
Bailey E, Wojcik J, Rahn M, Roos F, Spooren A, Koshibu K. Bailey E, et al. Int J Mol Sci. 2025 Sep 24;26(19):9343. doi: 10.3390/ijms26199343. Int J Mol Sci. 2025. PMID: 41096614 Free PMC article. Clinical Trial.
Microalgae offer a promising sustainable source of essential nutrients, docosahexaenoic acid (DHA), and eicosapentaenoic acid (EPA). DHA and EPA are mainly obtained through fish, which are limited in number due to global climate change. ...
Microalgae offer a promising sustainable source of essential nutrients, docosahexaenoic acid (DHA), and eicosapentaenoic ac …
Multicenter phase II study on the efficacy of an oral nutritional supplement containing eicosapentaenoic acid in advanced gastric cancer patients with cachexia.
Kawabata R, Nishikawa K, Kawase T, Kawada J, Kimura Y, Kashima Y, Ueda S, Takeno A, Shimomura K, Imamura H. Kawabata R, et al. Gastric Cancer. 2025 Jul;28(4):641-651. doi: 10.1007/s10120-025-01605-x. Epub 2025 Mar 19. Gastric Cancer. 2025. PMID: 40106056 Clinical Trial.
BACKGROUND: Cachexia is a common complication in advanced gastric cancer (AGC). Eicosapentaenoic acid (EPA) may ameliorate cachexia. This single-arm, phase II study assessed the potential benefit of an oral nutritional supplement containing EPA (ONS-EPA) for cachexi …
BACKGROUND: Cachexia is a common complication in advanced gastric cancer (AGC). Eicosapentaenoic acid (EPA) may ameliorate cac …
2,117 results